outcomes of autosct, allosct & car-t cell therapy in patients with tp53-altered mcl
Published 1 year ago • 283 plays • Length 2:48Download video MP4
Download video MP3
Similar videos
-
4:39
intermittent neutrophil recovery associated with improved car-t outcomes in r/r lbcl
-
3:15
outcomes and management of patients who develop covid-19 after cd19-targeted car-t therapy
-
3:01
mechanisms of antigen escape following cd19-directed car-t therapy
-
2:11
improving treatment outcomes of car t-cell therapy
-
1:58
patient-reported outcomes vs performance-based metrics: the effects of car-t therapy on cognition
-
4:24
investigating production failure and out-of-specification production of car t-cell therapeutics
-
3:38
mechanisms of resistance to car-t in all: t-cell fitness, antigen loss and immunological rejection
-
3:21
safety management of car-t cell therapy in dlbcl
-
3:21
patient-reported outcomes with car t-cell therapy
-
3:43
the future of car-t therapy
-
1:49
car-t cell approaches in cll: current progress & future directions
-
3:56
considerations and challenges of integrating car-t and transplantation in b-all
-
3:07
the role of bridging and timing in car-t
-
4:34
future perspectives in car-t therapy
-
1:58
real-world data on the efficacy of car-t therapy in patients with all
-
5:09
the evolving role of nurses in the field of car-t
-
4:49
patient-reported outcomes in car-t recipients
-
9:58
the management & optimization of car t-cell therapy in myeloma
-
2:05
novel car-t constructs being explored in myeloma: t-charge platform